Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico
Article
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
The coordinated efforts to stop the spread of the severe acute respiratory syndrome corona-virus 2 (SARS-CoV2) include massive immunization of the population at a global scale. The humoral immunity against COVID-19 is conferred by neutralizing antibodies (NAbs) that occur during the post-infection period and upon vaccination. Here, we provide robust data showing that potent neutralizing antibodies are induced in convalescent patients of SARS-CoV-2 infection who have been immunized with different types of vaccines, and patients with no previous history of COVID-19 immunized with a mixed vaccination schedule regardless of the previous infection. More importantly, we showed that a heterologous prime-boost in individuals with Ad5-nCoV (Cansino) vaccine induces higher NAbs levels in comparison to a single vaccination scheme alone. © 2022 Cervantes-Luevano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
publication date
funding provided via
published in
Research
keywords
ad26.cov2.s vaccine; convidicea; coronavac; elasomeran; neutralizing antibody; tozinameran; vaxzevria; coronavirus spike glycoprotein; neutralizing antibody; spike protein, SARS-CoV-2; virus antibody; virus RNA; virus vaccine; adult; aged; antibody detection; antibody production; antibody response; antibody titer; Article; controlled study; convalescence; coronavirus disease 2019; drug efficacy; female; human; human cell; humoral immunity; infection risk; male; Mexico; nonhuman; risk reduction; SARS-CoV-2 Alpha; SARS-CoV-2 Delta; SARS-CoV-2 Epsilon; Severe acute respiratory syndrome coronavirus 2; sex difference; vaccination; prevention and control; secondary immunization; vaccination; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Humans; Immunization, Secondary; Mexico; RNA, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccination; Viral Vaccines
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue